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Abstract
The beneﬁt of pharmacokinetic assessment of sunitinib remains unknown. We reported that patients with total
sunitinib (sunitinibD its active metabolite SU12662) ‡ 100 ng/mL showed high incidence of Grade ‡ 3 toxicities
and worsening clinical outcomes. Thus, pharmacokinetic assessment of sunitinib could be helpful for dose
optimization.
Background: Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib
pharmacokinetics shows a large interpatient variability. Patients and Methods: A retrospective, observational clinical
study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the ﬁrst
cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib
concentration in a steady state during the ﬁrst cycle. Results: The median total sunitinib concentration was 91.8 ng/mL
(range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of throm-
bocytopenia, anorexia, and fatigue. Patients with  100 ng/mL total sunitinib (n ¼ 8), compared with patients with
< 100 ng/mL (n ¼ 13), had a greater incidence of Grade  3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]).
Patients with < 100 ng/mL total sunitinib had signiﬁcantly longer time to treatment failure (TTF) and progression-free
survival (PFS) time than patients with  100 ng/mL (median TTF, 590 vs. 71 days; P ¼ .04; median PFS, 748 vs. 238
days; P ¼ .02). Conclusion: Results of this study suggest that therapeutic drug monitoring of sunitinib could be useful
for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is 
100 ng/mL, to avoid unnecessary early discontinuation of treatment.
Clinical Genitourinary Cancer, Vol. 13, No. 4, 350-8 ª 2015 Elsevier Inc. All rights reserved.
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Clinical Genitourinary Cancer August 2015receptors, and stem-cell factor receptor. It has been approved by the
US Food and Drug Administration for the treatment of advanced
and/or metastatic renal cell carcinoma (RCC) as the ﬁrst-line
treatment.1 Sunitinib frequently induces severe toxicities such as
thrombocytopenia, anorexia, fatigue, hand-foot syndrome (HFS),
and bleeding events.1 In addition, sunitinib induces rare, but
potentially life-threatening events such as intestinal perforation,
interstitial lung disease, and would healing complication.2-4 Because
these toxicities are difﬁcult to treat and anticipate, dose reduction or
discontinuation is generally carried out in daily clinical settings. As a
consequence, physicians must closely monitor all patients who have
started sunitinib treatment. Against this background, a predictive
marker for preventing severe sunitinib-induced toxicities is needed.1558-7673/$ - see frontmatter ª 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.clgc.2015.01.007
Therapeutic drug monitoring (TDM) has been widely used to
improve efﬁcacy and to avoid adverse events for various drugs.5
At present, although many anticancer agents show large interindi-
vidual variability for pharmacokinetics (PK), TDM has not been
routinely used in chemotherapy management. Recently, clinical
studies have reported that trough imatinib plasma levels are associated
with cytogenetic and molecular response in chronic myeloid leuke-
mia.6,7 Regarding toxicity, several studies have demonstrated that the
area under the curve (AUC) of erlotinib was associated with the
occurrence of skin toxicity.8,9 Implementation of TDM might
contribute to optimal dose adjustment for other oral molecular-
targeted anticancer agents including sunitinib. In fact, considerable
interindividual differences in sunitinib PK have been observed.10 The
reason for severe toxicity in some patientsmight be the interindividual
variation in serum levels of sunitinib. However, a pharmacokinetic
(PK) approach to evaluate the side effects of sunitinib is lacking.
Furthermore, information on the associations between sunitinib PK
and clinical outcomes and pharmacogenomic factors is insufﬁcient.
Sunitinib is primarily metabolized by cytochrome P450 (CYP)
3A4 to the equally active SU12662. SU12662 is further metabo-
lized to inactive moieties by CYP3A4.11 Previous studies have
reported that sunitinib is a substrate for adenosine triphosphate-
binding cassette (ABC) transporters, ABCG212 and ABCB1,13
which affect the intestinal absorption and biliary excretion of
various drug substrates.14 In this study, we evaluated polymorphism
in CYP3A5 (6986G>A), ABCG2 (421C>A, 34G>A, 1143C>T),
and ABCB1 (1236C>T, 2677G>T/A, 3435C>T) (Table 1).
Regarding the ABCB1 variants, we assessed the ABCB1 1236-2677-
3435 TTT haplotype, which is associated with low expression.15
In the present study, the primary aim was to evaluate the
association of sunitinib concentration with sunitinib-induced
toxicity in patients with RCC. The secondary aim was to estimate
the association of sunitinib PK with clinical outcome and genetic
polymorphisms related to the PK of sunitinib.
Patients and Methods
Patients
This was a 2-institution study conducted at Shiga University of
Medical Science Hospital and Shiga Medical Center for Adults.
Twenty-one Japanese RCC patients treated with sunitinib were
enrolled between September 2010 and March 2013. Eligibility
criteria included histological conﬁrmation and Eastern Cooperative
Oncology Group performance status of 0, 1, or 2. This study was
approved by the relevant institutional review boards.Table 1 Selected SNPs Related to Sunitinib Pharmacokinetics
Gene SNPs rs Number Region
CYP3A5 CYP3A5 6986G>A rs776746 Intron
ABCG2 ABCG2 421C>A rs2231142 Nonsynonymous Q141K
ABCG2 ABCG2 34G>A rs2231137 Nonsynonymous V12M
ABCG2 ABCG2 1143C>T rs2622604 Intron
ABCB1 ABCB1 1236C>T rs1128503 Synonymous G412G
ABCB1 ABCB1 2677G>T/A rs2032582 Nonsynonymous A893S/T
ABCB1 ABCB1 3435G>T rs104642 Synonymous I1445I
Abbreviation: SNP ¼ single-nucleotide polymorphism.Treatment Plan
Sunitinib was administered at a dose of 50 mg, 37.5 mg, or
25 mg daily based on the treating physicians’ recommendation for
4 weeks of a 6-week cycle for the ﬁrst cycle. Subsequently, dose
reduction or discontinuation was adjusted based on adverse events
or disease progression.
Assessment of Safety and Efﬁcacy
All adverse events were graded according to the Common
Toxicity Criteria for Adverse Effects version 4.0. The worst clini-
cally signiﬁcant treatment-associated toxicities were analyzed. We
also examined major bleeding events, as previously deﬁned.16 The
best tumor response was assessed using the Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1.17 Time for
assessment was dictated by the individual institutional policies. To
evaluate drug exposure and the safety/efﬁcacy relationship, we
grouped the population into patients with “low” exposure and
“high” exposure. In this study, we used a total sunitinib
(sunitinib þ SU12662) concentration of 100 ng/mL as the cutoff
value, which was previously reported as being associated with most
patients experiencing dose-limiting toxicity.18 Toxicity and clinical
outcome due to sunitinib were compared between the 2 groups.
Assessment of Serum Level of Sunitinib
After informed consent had been obtained from the patients,
blood samples were collected before administration at a steady state
(days 10-28) after the initiation of sunitinib treatment during the
ﬁrst cycle. We retrospectively evaluated the serum concentrations of
sunitinib and its major metabolite, SU12662, using stored blood
samples. Blood samples were drawn into a sterilized vacuum tube
for separation just before sunitinib administration. All samples were
centrifuged at 1700g and 4C for 10 minutes, and serum was
separated and stored at 20C.
Sunitinib and SU12662 were measured using high-performance
liquid chromatography, as previously described.19 The observed
intraday and interday assay imprecision and inaccuracy were
< 10%. The lower limits of quantiﬁcation of sunitinib and
SU12662 were 10 ng/mL and 5 ng/mL, respectively.
Single-Nucleotide Polymorphisms Related to the PK of
Sunitinib
Genomic DNA was extracted from the blood using DNA Extract
All Reagents (Applied Biosystems, Foster City, CA). Subsequently,
genotyping was performed using TaqMan Single-Nucleotide Poly-
morphism (SNP) genotyping assay (Applied Biosystems) in a Step
One Plus Real time Polymerase Chain Reaction system (Applied
Biosystems). Ampliﬁcation conditions were 95C for 20 seconds,
40 cycles of 95C for 3 seconds, and 60C for 20 seconds.
Statistical Analysis
Descriptive data are expressed as mean  SD or median.
Continuous variables were compared using the ManneWhitney
U test. Categorical variable were compared using the c2 test or
Fisher exact test. The correlation between serum concentration of
sunitinib and blood cell count was determined using the Spearman
test. The correlation between the severity of nonhematological
toxicities and total sunitinib concentration was evaluated using theClinical Genitourinary Cancer August 2015 - 351
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352 -JonckheereeTerpsta test. Time-to-event variables were estimated
using the KaplaneMeier method and log rank test. Time to
treatment failure (TTF) was deﬁned as the period from the ﬁrst day
of sunitinib treatment until cessation of sunitinib treatment for any
cause. Progression-free survival (PFS) was deﬁned from the date of
treatment initiation to the date of objective tumor progression or
death. Overall survival (OS) was deﬁned from the date of sunitinib
initiation until the date of death. Patients lost to follow-up were
censored at the time of last contact. The cutoff date for this analysis
was March 31, 2014. Median follow-up was 482 days (range,
48-1001 days). Allele frequencies were tested for HardyeWeinberg
equilibrium using the c2 test. Correlations between genotypes
related to sunitinib PK and the dose-adjusted total sunitinib
concentration were evaluated using 1-way analysis of variance and
Tukey test. All comparison tests were 2-sided. A P < .05 was
considered to be statistically signiﬁcant. All statistical analyses were
performed using SPSS __ version 22.0.
Results
Patient Characteristics
Twenty-one patients were treated with sunitinib. Baseline char-
acteristics are shown in Table 2. The median age was 68 (range,
56-83) years, and 18 patients (85.7%) had clear-cell histology. Pa-
tients were treated with sunitinib starting at doses of 50 mg (n¼ 11),Table 2 Patient Characteristics
Characteristic Total (n [ 21
Median Age (Range), Years 68 (56-83)
Sex (Male/Female) 17/4
Median Weight (Range), kg 56 (37-80)
Median AST (Range), IU/L 22 (9-86)
Median ALT (Range), IU/L 13 (6-104)
Median eGFR (Range), mL/min/1.73m2 41.8 (6.2-80.4)
Median Sunitinib Concentration (Range), ng/mL 64.6 (30.6-137)
Median SU12662 Concentration (Range), ng/mL 22.5 (12.4-68.5
Median Total Sunitinib Concentration (Range), ng/mL 91.8 (49.8-205)
Initial Dose, n (%)
50 mg 11 (52.4)
37.5 mg 5 (23.8)
25 mg 5 (23.8)
Histology, n (%)
Clear cell 18 (85.7)
Papillary 3 (14.3)
Previous Treatment, n (%)
No 12 (57.1)
Sorafenib 5 (23.8)
Immunotherapy 4 (19.2)
ECOG Performance Status, n (%)
0 16 (76.2)
1 3 (14.3)
2 2 (9.5)
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; ECOG ¼ Easte
Clinical Genitourinary Cancer August 201537.5 mg (n ¼ 5), and 25 mg (n ¼ 5) daily. The median trough total
sunitinib concentration was 91.8 (range, 49.8-205) ng/mL.
Association of Toxicities With Total Sunitinib
Concentration
In the ﬁrst cycle of sunitinib, a clear inverse correlation was found
between the total sunitinib concentration and the blood platelet
count at nadir (r ¼ 0.53; P ¼ .01), but not hemoglobin level
(r ¼ 0.04; P ¼ .86) or leukocyte count (r ¼ 0.14; P ¼ .55;
Figure 1).
A positive trend was observed between total sunitinib concen-
tration and higher-grade toxicity of anorexia and fatigue
(Figure 2A, B). In addition, total sunitinib concentration was not
correlated with the severities of HFS and hypertension (Figure 2C,
D). The mean total sunitinib concentration was greater in patients
with bleeding events (n ¼ 10) than in those without them (n ¼ 11;
116  43.4 vs. 77.2  22.2 ng/mL, respectively; P ¼ .13;
Figure 2E).
Association of Dose Reduction or Discontinuation of
Sunitinib With Total Sunitinib Concentration
In the low-exposure group (total sunitinib < 100 ng/mL;
n ¼ 13), 3 patients (23.1%) experienced Grade 3 thrombocyto-
penia during the ﬁrst cycle. Dose reductions from 50 mg to 37.5 mg)
Total Sunitinib Concentration
P<100 (n [ 13) ‡100 (n [ 8)
68 (56-83) 70 (59-79) .92
10/3 7/1 .50
56 (37-74) 50 (45-80) .33
22 (9-59) 26 (19-86) .41
16 (7-59) 11 (6-104) .46
41.5 (6.2-80.4) 50.8 (30.3-76.7) .50
49.8 (30.6-75.6) 108 (64.7-137) <.01
) 22.7 (12.4-43.7) 22.3 (13.0-68.5) .75
80.2 (49.8-93.5) 125 (106-205) <.01
4 (30.8) 7 (87.5) .03
5 (38.4) 0 (0.0)
4 (30.8) 1 (12.5)
11 (84.6) 7 (87.5) .62
2 (15.4) 1 (12.5)
7 (53.8) 5 (62.5) .67
4 (30.8) 1 (12.5)
2 (15.4) 2 (25.0)
10 (76.9) 6 (75.0) .93
2 (15.4) 1 (12.5)
1 (7.7) 1 (12.5)
rn Cooperative Oncology Group; eGFR ¼ estimated glomerular ﬁltration rate.
Figure 1 The Relationship Between Total Sunitinib Concentration and Hematological Toxicity. For the First Cycle of Sunitinib
Treatment, (A) Platelet Count, (B) Hemoglobin Level, and (C) Leukocyte Count at Nadir Were Compared With Trough Total
Sunitinib (Sunitinib D SU12662) at a Steady State in 21 Patients With Renal Cell Carcinoma. Each Circle Represents an
Individual Patient
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Satoshi Noda et alwere performed in 2 patients, which resulted in attenuation of the
thrombocytopenia. In this group, the toxicities of sunitinib therapy
were mild (Grade  1 toxicities), except for the thrombocytopenia,
and controllable. The ﬁnal reasons for sunitinib discontinuation
were disease progression (n ¼ 5), interstitial lung disease (n ¼ 2),
Grade 3 anorexia (n ¼ 2), and Grade 3 pancreatitis (n ¼ 1).
In the high-exposure group (total sunitinib  100 ng/mL;
n ¼ 8), 6 of the 8 patients (75.0%) experienced Grade  3 tox-
icities during the ﬁrst cycle. Because of its toxicities, dose re-
ductions from 50 mg to 37.5 mg were performed in 5 patients. In
2 patients, the dose was reduced from 50 mg to 25 mg. In this
group, 3 patients, who were managed as outpatients, were hospi-
talized because of grade 3 anorexia (n ¼ 2) and intestinal perfo-
ration (n ¼ 1). Additionally, 1 patient experienced protracted
wound healing for the ﬁrst cycle. As a consequence, sunitinib was
discontinued in 7 patients who experienced Grade 3 anorexia
(n ¼ 3), Grade 3 fatigue (n ¼ 3), and intestinal perforation
(n ¼ 1). Treatment of the patient who experienced intestinal
perforation was started with sunitinib at 50 mg daily for 4 weeks of
a 6-week cycle. This patient needed a dose reduction to 37.5 mg
after 1 cycle of sunitinib because of Grade 3 thrombocytopenia.
Six days after discontinuation of the second cycle of sunitinib, he
presented with abdominal pain and muscle guarding. Computed
tomography scans showed free air in the upper abdomen. Emer-
gency laparotomy revealed localized perforation of the sigmoidcolon. Resection of the sigmoid colon and colostomy were per-
formed, and he recovered within 14 days. As shown in Figure 3,
serum total sunitinib concentration was 205 ng/mL on day 16 of
the ﬁrst cycle. It was reported that sunitinib was effective at total
plasma concentrations of 50 to 100 ng/mL in a vivo study.20
Serum total sunitinib concentrations of the second cycle ranged
from 90 to 160 ng/mL.
Association of Efﬁcacy With Total Sunitinib
Concentration
Eighteen of the 21 patients (85.7%) were included in the analysis
of efﬁcacy end points. A waterfall plot of the greatest percentage
changes from baseline in the sum of the longest diameters of target
lesions according to a total sunitinib concentration of  100
ng/mL, or < 100 mg/mL are displayed in Figure 4.
In the low-exposure group (total sunitinib < 100 ng/mL;
n ¼ 13), partial responses determined according to RECIST were
achieved in 3 patients (23.1%). Stable disease was observed in 8
patients (61.5%). In 1 patient, the efﬁcacy could not be conﬁrmed
because of transfer to another hospital. One patient was not assess-
able because of early unacceptable toxicity before the ﬁrst assessment.
In the high-exposure group (total sunitinib  100 ng/mL;
n ¼ 8), the best response of stable disease was observed in 7 patients
(87.5%). One patient was not assessable because of early unac-
ceptable toxicity before the ﬁrst assessment.Clinical Genitourinary Cancer August 2015 - 353
Figure 3 A Case of Perforation of the Sigmoid Colon Possibly
Related to High Exposure to Sunitinib. Serum
Concentrations of Total Sunitinib During Sunitinib
Therapy in a Patient Who Experienced Intestinal
Perforation. Arrow Indicates the Occurrence of
Perforation of the Sigmoid Colon. Gray Area Shows
the Therapeutic Range of Sunitinib (50-100 ng/mL)20
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Figure 2 The Relationship Between Total Sunitinib Concentration and Nonhematological Toxicity. For the First Cycle of Sunitinib
Treatment, (A) Anorexia, (B) Fatigue, (C) Hand-Foot Syndrome, (D) Hypertension, and (E) Bleeding Event Were Compared With
Trough Total Sunitinib at a Steady State in 21 Patients With Renal Cell Carcinoma. All Adverse Events Were Graded Using the
Common Toxicity Criteria for Adverse Effects Version 4.0. Each Circle Represents an Individual Patient
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354 - Clinical Genitourinary Cancer August 2015Association of TTF, PFS, and OS With Total Sunitinib
Concentration
The median TTF, PFS, and OS were 163 days (95% conﬁdence
interval [CI], 9.12-317), 590 days (95% CI, 58.3-1122), and 939
days (95% CI, 585-1293), respectively. Additionally, a subgroup
analysis of TTF, PFS, and OS was performed using total sunitinib
concentration for the ﬁrst cycle.
The patients with < 100 ng/mL total sunitinib (n ¼ 13) had
signiﬁcantly longer TTF than patients with  100 ng/mL (n ¼ 8;
median, 590 vs. 71 days; P ¼ .04; Figure 5A). Patients with < 100
ng/mL total sunitinib had signiﬁcantly longer PFS than patients
with  100 ng/mL (median, 748 vs. 238 days; P ¼ .02; Figure 5B).
Patients with < 100 ng/mL total sunitinib showed only a tendency
for signiﬁcantly longer OS than patients with  100 ng/mL (me-
dian, 939 vs. 570 days; P ¼ .07; Figure 5C).
Association of Total Sunitinib Concentration With SNPs
Related to the PK of Sunitinib
Pharmacogenomic data were available for 21 patients. The
allele frequencies of polymorphism in ABCG2, ABCB1, and
CYP3A5 are shown in Table 3. These SNPs were in
HardyeWeinberg equilibrium (P > .05), except for the CYP3A5
(6986G>A). However, the observed deviation was small with
Figure 4 Waterfall Plot of the Greatest Percentage Change From Baseline in the Sum of the Longest Diameters of Target Lesions. Open
Squares, Patients With a Total Sunitinib Concentration < 100 ng/mL; Closed Squares, Patients With a Total Sunitinib
Concentration ‡ 100 ng/mL
Patients with total sunitinib ≥100 ng/mL (n = 7)
Patients with total sunitinib <100 ng/mL (n = 11)
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Satoshi Noda et alP ¼ .01 for CYP3A5 (6986G>A). As shown in Figure 6, no
statistically signiﬁcant associations between SNPs related to the
PK of sunitinib and total sunitinib dose-adjusted concentration
were observed.
Discussion
Despite the excellent efﬁcacy of sunitinib, its severe toxicity is
becoming a central issue in the treatment of RCC. Identifying a
predictive marker of sunitinib toxicity is important to improve
sunitinib therapy management. High exposure to sunitinib might
be one of the reasons for the severe toxicities induced by it. In the
present study, we showed that some patients with  100 ng/mL
total sunitinib concentration were hospitalized because of its severe
toxicities during outpatient therapy. Among them, 1 patient had to
stop sunitinib permanently after 2 cycles because of intestinal
perforation. Of interest is the fact that this patient had extremely
high exposure to sunitinib (total trough sunitinib for the ﬁrst cycle:
205 ng/mL). This patient had the rare genotype combination of
ABCG2 and ABCB1; homozygosity for ABCG2 34G>A and the
ABCB1 1236-2677-3435 TTT haplotype, suggesting that the
functional loss of ABCG2 and ABCB1 might have contributed to
the substantial exposure to sunitinib. Another reason for a high
concentration in this patient is considered to be because of
drugedrug interaction. During sunitinib therapy, this patient had
taken azelnidipine, a CYP 3A4 inhibitor,21 in combination with it,
which could have been related to the high concentration of
sunitinib.
A previous meta-analysis indicated that increased serum AUC to
total sunitinib is associated with improved treatment outcomes and
some adverse effects.22 Although severe toxicity of sunitinib is
becoming a central issue in the treatment of RCC, a threshold forthe toxicity of sunitinib treatment has not been deﬁned. Further-
more, a recent study demonstrated that total trough sunitinib
concentration was highly correlated with its AUC0 to 24 hours.
23
Therefore, we consider that total sunitinib trough concentration is
a valid PK parameter for its toxicity. In a phase _ study, a case
presentation of 3 patients indicated that total sunitinib trough
concentration  100 ng/mL might be associated with dose-limiting
toxicity.18 In agreement with this study, we showed that most of the
patients with total trough sunitinib  100 ng/mL experienced
unacceptable toxicities. This could have led to early treatment
discontinuation or delayed administration, which resulted in
suboptimal efﬁcacy of sunitinib. In fact, in the present study, the
high-exposure group ( 100 ng/mL total sunitinib) showed a
shorter TTF and PFS. These observations suggest that  100
ng/mL total sunitinib trough concentration might be a limiting
factor leading to treatment discontinuation.
Preclinical studies have demonstrated that sunitinib is effective at
total plasma concentrations of 50 to 100 ng/mL.20 In a clinical trial,
Faivre et al18 reported that the total sunitinib concentration ob-
tained with a dose of 50 mg daily ranged from 50 to 100 ng/mL.
Uemura et al24 also reported that sunitinib was effective at plasma
concentrations  50 ng/mL in patients with metastatic RCC. In the
present study, 95.2% of patients (20/21) exceeded 50 ng/mL total
sunitinib, and these patients showed either a partial response or
stable disease as the best response. Additionally, considering suni-
tinib toxicity, when targeting  100 ng/mL total sunitinib, it is
difﬁcult to maintain sunitinib treatment for a long period of time.
Therefore, the target range could be a total sunitinib trough
concentration of 50 to 100 ng/mL during sunitinib therapy.
In this study, total sunitinib concentration was signiﬁcantly
associated with TTF and PFS. However, the difference betweenClinical Genitourinary Cancer August 2015 - 355
Figure 5 KaplaneMeier Curve of (A) Time to Treatment Failure (TTF), (B) Progression-Free Survival (PFS), and (C) Overall Survival (OS)
According to Sunitinib Exposure in Patients With Renal Cell Carcinoma. Solid Lines, Patients With a Total Sunitinib
Concentration < 100 ng/mL; Dotted Lines, Patients With a Total Sunitinib Concentration ‡ 100 ng/mL. Small Closed Diamond
Marks Represent Censored Patients (End of Follow-Up)
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356 -PFS and TTF was large. This apparent difference might be
explained by the fact that patients who discontinued sunitinib
treatment because of its severe toxicities have a greater frequency
compared with those who discontinued treatment because of
progression of disease (12 patients [57.1%] vs. 5 patients
[23.8%]). Considering that PFS includes time to diseaseTable 3 Polymorphism Genotype and Allele Frequency
Gene SNPs Patients
Homozyg
Wild Ty
CYP3A5 CYP3A5 6986G>A 21 13
ABCG2 ABCG2 421C>A 21 11
ABCG2 ABCG2 34G>A 21 15
ABCG2 ABCG2 1143C>T 21 17
ABCB1 ABCB1 1236C>T 21 2
ABCB1 ABCB1 2677G>T/A 21 3
ABCB1 ABCB1 3435G>T 21 4
Abbreviation: SNP ¼ single-nucleotide polymorphism.
Clinical Genitourinary Cancer August 2015progression from sunitinib discontinuation induced by toxicity,
PFS might be longer than TTF in the present study.
Our data showed that polymorphisms related to PK of sunitinib
was not related to total sunitinib dose-adjusted concentration.
However, previous preclinical and clinical studies reported that
functional loss of ABCG2 was associated with increased sunitinibous
pe Heterozygous
Homozygous
Variant Allele Frequency
4 4 0.286
8 2 0.286
5 1 0.167
4 0 0.095
6 13 0.761
10 8 0.619
11 6 0.547
Figure 6 The Relationship Between Total Sunitinib Concentration and Single Nucleotide Polymorphisms Related to the
Pharmacokinetics of Sunitinib. We Examined the Effect of Genetic Polymorphisms in (A) CYP3A5, (B-D) ABCG2, and (E)
ABCB1. C/D Ratio Represents Total Sunitinib Dose-Adjusted Concentration
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Satoshi Noda et alexposure and sunitinib-related toxicity.12,25-27 Of interest, our pa-
tient who experienced high exposure to sunitinib had the ABCG2
and ABCB1 variant, and had received a CYP3A4 inhibitor in
combination with sunitinib. Therefore, phenotypes of the PK
of sunitinib are multifactorial, and not only genetics but also
drug-drug interactions, poor compliance, and environment could
have an effect on sunitinib PK.
Conclusion
The present study showed that several side effects of sunitinib
were dose-dependent. Discontinuation occurred signiﬁcantly more
frequently in patients with total sunitinib trough concentration
 100 ng/mL. Dose reduction might be needed, especially when
the steady-state total sunitinib concentration is > 100 ng/mL.
These ﬁndings suggest that TDM of sunitinib could be helpful for
avoiding severe side effects, resulting in prolonged TTF and PFS
with sunitinib therapy. However, these results are debatable because
the number of patients examined was very small and there were
several differences in their background. To conﬁrm these ﬁndings,
large prospective PK studies should be performed.
Clinical Practice Points
 Sunitinib, an oral multitargeted tyrosine inhibitor, has shown
single-agent activity in patients with metastatic RCC. Sunitinib
PK show a large interpatient variability. However, information
on pharmacokinetic assessment of sunitinib is limited. In this retrospective, observational study, we explored the
PK relationship with safety or efﬁcacy of sunitinib in 21
patients with RCC. We found that the severity of throm-
bocytopenia, anorexia, and fatigue appeared to be dose-
dependent. Patients with  100 ng/mL total sunitinib
(n ¼ 8), compared with patients with < 100 ng/mL (n ¼
13), had a greater incidence of Grade  3 toxicities (6 pa-
tients [75%] vs. 3 patients [23%]). Furthermore, we indi-
cated that patients with < 100 ng/mL total sunitinib had
signiﬁcantly longer TTF and PFS than patients with 
100 ng/mL.
 These ﬁndings suggested that TDM of sunitinib could be helpful
for avoiding severe toxicities, resulting in prolonged TTF and
PFS with sunitinib therapy. However, this was a retrospective
analysis of a small number of patients, which consisted of a
heterogeneous population. Therefore, these results need to be
validated in a large prospective study.Acknowledgments
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